This company listing is no longer active
Calliditas Therapeutics Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
02 Sep 24 | SellSEK 11,826,880 | Elmar Schnee | Individual | 56,860 | SEK 208.00 | |
02 Sep 24 | SellSEK 2,080,000 | Henrik Stenqvist | Individual | 10,000 | SEK 208.00 | |
02 Sep 24 | SellSEK 3,380,000 | Fredrik Johansson | Individual | 16,250 | SEK 208.00 | |
02 Sep 24 | SellSEK 152,903,298 | Renee Aguiar-Lucander | Individual | 735,112 | SEK 208.00 | |
04 Jul 24 | SellSEK 13,885,234 | Fredrik Johansson | Individual | 67,439 | SEK 206.00 | |
03 Jul 24 | SellSEK 5,358,844 | Frank Bringstrup | Individual | 26,319 | SEK 205.80 | |
01 Jul 24 | SellSEK 10,458,016 | Richard Philipson | Individual | 50,885 | SEK 205.56 | |
04 Jun 24 | BuySEK 1,105,603,625 | Asahi Kasei Corporation | Company | 5,367,206 | SEK 208.65 |
Insider Trading Volume
Insider Buying: 0A5R insiders have only sold shares in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
Individual Insiders | 91,884 | 0.144% |
VC/PE Firms | 2,851,758 | 4.45% |
Institutions | 12,719,910 | 19.9% |
Public Companies | 48,355,697 | 75.5% |
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
48,355,697 | SEK 10.1b | 894% | no data | |||
2,851,758 | SEK 593.2m | 0.63% | 85.68% | |||
2,268,444 | SEK 471.8m | 7.27% | 0.17% | |||
1,738,975 | SEK 361.7m | 0% | 0.42% | |||
1,636,520 | SEK 340.4m | 29.2% | 20.88% | |||
1,636,520 | SEK 340.4m | 3.71% | 0.13% | |||
1,452,884 | SEK 302.2m | -24.8% | 8.64% | |||
1,215,238 | SEK 252.8m | 1.53% | 0.15% | |||
1,085,612 | SEK 225.8m | -31.4% | 0.03% | |||
960,730 | SEK 199.8m | 0% | 60.61% | |||
526,619 | SEK 109.5m | 0% | 0.02% | |||
373,402 | SEK 77.7m | 0% | 0.01% | |||
339,060 | SEK 70.5m | 0% | 26.7% | |||
336,007 | SEK 69.9m | 0% | 0.02% | |||
192,230 | SEK 40.0m | 0% | 0.02% | |||
164,186 | SEK 34.2m | 0% | 2.83% | |||
133,833 | SEK 27.8m | 0% | 0.16% | |||
121,121 | SEK 25.2m | 0% | 0.17% | |||
102,506 | SEK 21.3m | 0% | 0.01% | |||
71,000 | SEK 14.8m | 0% | no data | |||
70,000 | SEK 14.6m | -55.7% | 0.22% | |||
53,199 | SEK 11.1m | 0% | no data | |||
40,898 | SEK 8.5m | 0.77% | 0.01% | |||
37,276 | SEK 7.8m | 0% | 0.01% | |||
36,000 | SEK 7.5m | 0% | 0.14% |
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/10/11 00:55 |
End of Day Share Price | 2024/10/11 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Calliditas Therapeutics AB (publ) is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ingird Gafanhão | Bryan Garnier & Co |
Alexandru Cogut | Bryan Garnier & Co |
Erik Hultgård | Carnegie Investment Bank AB |